Abstract
In research for a new immunomodulator, we discoverd a novel hydroxypiperidine derivative 9h which was a potent inhibitor of IL-15induced T cell activation. Further modification of 9h gave a potent and orally active agent 10 which was effective in a mouse CIA model.
Keywords: Phenylpyrazoleanilide, IL-15, Prodrug, CIA
Letters in Drug Design & Discovery
Title: Phenylpyazoleanilides as a Potent Inhibitor of IL-15 Dependent T Cell Proliferation. Part 1: A New Class of Orally Available Immunomodulators
Volume: 5 Issue: 2
Author(s): Hiroyuki Ushio, Seigo Ishibuchi, Kunitomo Adachi, Kouichi Oshita and Kenji Chiba
Affiliation:
Keywords: Phenylpyrazoleanilide, IL-15, Prodrug, CIA
Abstract: In research for a new immunomodulator, we discoverd a novel hydroxypiperidine derivative 9h which was a potent inhibitor of IL-15induced T cell activation. Further modification of 9h gave a potent and orally active agent 10 which was effective in a mouse CIA model.
Export Options
About this article
Cite this article as:
Ushio Hiroyuki, Ishibuchi Seigo, Adachi Kunitomo, Oshita Kouichi and Chiba Kenji, Phenylpyazoleanilides as a Potent Inhibitor of IL-15 Dependent T Cell Proliferation. Part 1: A New Class of Orally Available Immunomodulators, Letters in Drug Design & Discovery 2008; 5 (2) . https://dx.doi.org/10.2174/157018008783928427
DOI https://dx.doi.org/10.2174/157018008783928427 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Matrix Metalloproteinases in Acute Inflammatory Shock Syndromes
Combinatorial Chemistry & High Throughput Screening Antioxidants Suppress Th1-Type Immune Response In Vitro
Drug Metabolism Letters The Histone Deacetylase SIRT6: At the Crossroads Between Epigenetics, Metabolism and Disease
Current Topics in Medicinal Chemistry Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry
Current Medicinal Chemistry Prevention and Therapeutic Strategies of Thromboembolic Events in Patients with Inflammatory Bowel Diseases: A Report of Three Cases
Current Drug Targets Prospects for Plant-Derived Chemopreventive Agents Exhibiting Multiple Mechanisms of Action
Current Medicinal Chemistry - Anti-Cancer Agents Pathogenesis and Immune Status in COVID-19 Pneumonia - A Minireview
Coronaviruses Protease-Activated Receptors as Therapeutic Targets in Visceral Pain
Current Neuropharmacology PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?
Current Pharmaceutical Design Targeting the JAK/STAT Signaling Pathway for Breast Cancer
Current Medicinal Chemistry Synthesis, Characterization, Antitubercular and Anti-Inflammatory Activity of New Pyrazolo[3,4-d]Pyrimidines
Combinatorial Chemistry & High Throughput Screening The Role of Coagulation and Fibrinolysis in the Pathogenesis of Acute Lung Injury
Current Respiratory Medicine Reviews Osthole: A Multifunctional Natural Compound with Potential Anticancer, Antioxidant and Anti-inflammatory Activities
Mini-Reviews in Medicinal Chemistry Nanoparticle-Based Diagnosis and Therapy
Current Drug Targets The Close Interplay of Nitro-Oxidative Stress, Advanced Glycation end Products and Inflammation in Inflammatory Bowel Diseases
Current Medicinal Chemistry Does the MK2-dependent Production of TNFα Regulate mGluR-dependent Synaptic Plasticity?
Current Neuropharmacology Cathepsin K Inhibitors: A Novel Target but Promising Approach in the Treatment of Osteoporosis
Current Drug Targets Pleiotropic Effects of Statins - Clinical Evidence
Current Pharmaceutical Design RNA Base Damage and Repair
Current Pharmaceutical Biotechnology Pharmaceutical Nanotechnology United States Patent Watch (July to September 2016)
Pharmaceutical Nanotechnology